Search Results
Jul 23, 2026, 09:00 ET ERAS INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS
Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015.
More news about: Hagens Berman Sobol Shapiro LLP
Jul 22, 2026, 18:45 ET ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, throughout the Class Period. According to the complaint, Erasca repeatedly touted ERAS-0015 as a potential "best-in-class" therapy and highlighted purportedly superior preclinical results compared
More news about: THE ROSEN LAW FIRM, P. A.
Jul 22, 2026, 16:00 ET Observational Clinical Study Shows 98% of Surgical Patients Achieved Normothermia Using the Hot Pink Pad™ as the Foundation of a Perioperative Warming Strategy
bundle.Kimberly Godawa, RN, MSN, CCRN, ERAS Coordinator, described the clinical value of this approach:"The Hot Pink Pad helps patients return to their pre-op temperature more quickly, which greatly supports our ERAS program. It's a welcome addition to our normothermia
More news about: Xodus Medical
Jul 22, 2026, 12:26 ET NASDAQ: ERAS CLASS ACTION NOTICE: Berger Montague Encourages Erasca, Inc. (NASDAQ: ERAS) Investors to Inquire About a Securities Fraud Class Action
Company's lead product candidate, ERAS-0015, is a pan-RAS molecular glue in development for the treatment of patients with RAS-mutated solid tumors.According to the complaint, throughout the Class Period, Defendants made repeatedly positive public statements touting ERAS-0015 as a potential "best-in-class"
More news about: Berger Montague
Jul 22, 2026, 10:07 ET ERAS Deadline Alert: Levi & Korsinsky Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026
Promoting ERAS-0015 as a "Best-in-Class" Drug Candidate, Costing Investors $11.59 Per ShareNEW YORK, July 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Erasca, Inc. (NASDAQ: ERAS) that a securities
More news about: Levi & Korsinsky, LLP
Jul 22, 2026, 06:00 ET ERAS INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS
Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015.
More news about: Hagens Berman Sobol Shapiro LLP
Jul 21, 2026, 16:26 ET ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015.
More news about: Hagens Berman Sobol Shapiro LLP
Jul 21, 2026, 12:00 ET Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
ERAS) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Jul 21, 2026, 10:05 ET ERAS Deadline Alert: The Gross Law Firm Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026
July 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Erasca, Inc. (NASDAQ: ERAS).
More news about: The Gross Law Firm
Jul 17, 2026, 22:45 ET ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, throughout the Class Period. According to the complaint, Erasca repeatedly touted ERAS-0015 as a potential "best-in-class" therapy and highlighted purportedly superior preclinical results compared
More news about: THE ROSEN LAW FIRM, P. A.
Jul 17, 2026, 22:00 ET Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Erasca, Inc. ("Erasca" or the "Company") (NasdaqGS: ERAS) of a class action securities lawsuit.
More news about: Kahn Swick & Foti, LLC
Jul 17, 2026, 15:15 ET G FUEL Teams Up with Marvel Animation's X-Men '97 Season 2 for Uncanny Golden Berry Collection
a 99% on Rotten Tomatoes as of today."X-Men '97" Season 2 continues with the heroic mutant team of X-Men, divided and thrown across different eras in time as they struggle to navigate their return home. Meanwhile, back in the 1990s, suspicious foes and new strains of mutant intolerance are on the
More news about: G FUEL
Jul 16, 2026, 10:07 ET ERAS DEADLINE: SueWallSt Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline
firms in the United States.Frequently Asked Questions About the ERAS LawsuitQ: What is the ERAS class action lawsuit about? A: A securities class action has been filed against Erasca, Inc. (NASDAQ: ERAS) alleging materially false and misleading statements between January 14,
More news about: SueWallSt.com
Jul 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
market hours on April 27, 2026, Erasca reported preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a "Grade 3 TRAE of pneumonitis" that "progressed to Grade
More news about: Pomerantz LLP
Jul 16, 2026, 09:00 ET ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015.
More news about: Hagens Berman Sobol Shapiro LLP
Jul 15, 2026, 20:00 ET ERAS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Erasca Class Action Lawsuit
reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015 and other product candidates were based on
More news about: Robbins Geller Rudman & Dowd LLP
Jul 15, 2026, 13:12 ET SEABOURN UNVEILS DETAILS OF 'THE RUBY COLLECTION': 54 VOYAGES ACROSS OCEAN AND EXPEDITION FOR ITS 40TH ANNIVERSARY IN 2028
onboard enhancements inspired by the Ruby Jubilee, from specialty events and signature celebrations to themed entertainment and enrichment inspired by eras past. The Ruby Collection voyages will feature additional celebratory touches designed to bring Seabourn's 40-year story to life on board. Seabourn
More news about: Seabourn
Jul 15, 2026, 10:07 ET ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
must be filed with the Court by August 10, 2026.Frequently Asked Questions About the ERAS LawsuitQ: Who is eligible to join the ERAS investor lawsuit? A: Investors who purchased ERAS stock or securities between January 14, 2025 and April 26, 2026 and suffered financial losses
More news about: Levi & Korsinsky, LLP
Jul 14, 2026, 21:44 ET ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
compared the equivalence of its ERAS-0015 40 milligram dose cohort to RevMed's RMC-6236 400 milligram dose cohort. In addition, as recently as March 12, 2026, Erasca allegedly assured investors of its ERAS-0015 intellectual property protection, and touted that its ERAS-0015 has "in-licensed one
More news about: Hagens Berman Sobol Shapiro LLP
Jul 14, 2026, 12:00 ET Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
About?The complaint filed alleges that, between January 14, 2025 and April 26, 2026, Defendants failed to disclose to investors that: (1) ERAS-0015's preclinical data was based on improper comparisons to RevMed and placed Erasca at risk of violating patent and trade secret protections; and (2) as
More news about: Glancy Prongay Wolke & Rotter LLP
Jul 14, 2026, 10:07 ET The Gross Law Firm Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS
July 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Erasca, Inc. (NASDAQ: ERAS).
More news about: The Gross Law Firm
Jul 13, 2026, 08:04 ET The $10B TAVR Market Grew. Why Are Most Patients Still Untreated?
aortic stenosis mortality in the pre- and post-TAVR eras in the United States, 1999 to 2023. Journal of Invasive Cardiology. hmpgloballearningnetwork.com/site/jic/conference-coverage/national-trends-aortic-stenosis-mortality-pre-and-post-tavr-erasMedia Inquiries:Karla Jo
More news about: Anteris Technologies
Jul 13, 2026, 04:47 ET Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS
ERAS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ERAS during the class period listed are encouraged
More news about: DJS Law Group LLP
Jul 13, 2026, 03:41 ET ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
statements to the market. Erasca's Preclinical data on ERAS-0015 was built on an improper comparison to Revolution Medicines, Inc., which placed it at risk of violating patent protections. The Company lacked basis for its optimistic statements on ERAS-0015. Based on these facts, the Company's public statements
More news about: The Schall Law Firm
Jul 12, 2026, 20:16 ET ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, throughout the Class Period. According to the complaint, Erasca repeatedly touted ERAS-0015 as a potential "best-in-class" therapy and highlighted purportedly superior preclinical results compared
More news about: THE ROSEN LAW FIRM, P. A.